Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Cannabix Technologies (BLO) AI Stock Analysis

TSE:BLO

Cannabix Technologies

(CNQX:BLO)

Select Model
Rating:43Neutral
Price Target:CAD 0.48â–²(15.18% Upside)
Action:upgraded
Date:10/22/26

The score is primarily constrained by severe financial weaknesses, including persistent losses, lack of meaningful revenue, shrinking capital, and ongoing cash burn. Moderate short-term technical support provides some offset, but the negative P/E and absence of dividend support keep the overall score low.

Positive Factors
Low LeverageModest leverage reduces solvency pressure and gives the company more financial flexibility than a heavily indebted operation. Although the capital base is weakening, low debt exposure limits interest and refinancing burdens while management develops the company’s technology.
Negative Factors
Minimal Revenue and Persistent LossesThe company has not demonstrated meaningful revenue generation, while losses remain sizable and volatile. This indicates that the operating model has yet to cover its costs, leaving future progress dependent on successful commercialization rather than an established stream of recurring business income.

Cannabix Technologies (BLO) vs. iShares MSCI Canada ETF (EWC)

-60%-40%-20%0%20%40%60%TSE:BLO-30.83%EWC+21.27%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
Market Cap
CAD 37.08M
Dividend Yield
―
Average Volume (3M)
31.94K
Price to Earnings (P/E)
-13.2
Beta (1Y)
-0.11
Revenue Growth
―
EPS Growth
-84.43%
Country
Canada
Employees
0
Sector
Healthcare
Sector Strength
51
Industry
Other Precious Metals

Cannabix Technologies Business Overview & Revenue Model

Company Description

Cannabix Technologies Inc., a technology company, develops marijuana and alcohol breathalyzer technologies for employers, law enforcement, workplaces, and laboratories in the United States. It offers Cannabix Marijuana Breath Test (MBT) for Tetrahydr...

Cannabix Technologies Financial Statement Overview

Summary

The supplied income statement, balance sheet, and cash flow scores average approximately 20.3, but the component score is bounded at the required minimum of 37. Persistent losses, no meaningful revenue, shrinking equity and assets, and sustained negative operating and free cash flow are severe weaknesses; low debt provides limited support.

Income Statement

8Very Negative

Balance Sheet

34Negative

Cash Flow

19Very Negative
Financial statement breakdown
BreakdownTTMJul 2026Jul 2025Jul 2024Jul 2023Jul 2022
Income Statement
Total Revenue-100000
Gross Profit-261.54K-172.97K-168.52K-153.24K-126.29K-29.22K
EBITDA-5.73M-5.83M-4.42M-2.96M-2.01M-3.11M
Net Income-5.76M-5.76M-4.69M-3.13M-2.14M-3.37M
Balance Sheet
Total Assets2.21M2.21M3.00M4.70M6.95M8.76M
Cash, Cash Equivalents and Short-Term Investments1.59M1.59M2.35M4.26M6.52M8.45M
Total Debt160.06K160.06K158.65K154.58K132.54K0
Total Liabilities431.71K431.71K447.71K248.02K237.17K120.84K
Stockholders Equity1.78M1.78M2.55M4.45M6.71M8.64M
Cash Flow
Free Cash Flow-1.74M-1.74M-1.86M-2.11M-2.00M-2.13M
Operating Cash Flow-1.74M-1.74M-1.84M-2.08M-1.97M-2.13M
Investing Cash Flow00-17.54K-30.96K-28.65K-4,592
Financing Cash Flow968.26K968.26K-58.47K-143.53K10.88K492.50K

Cannabix Technologies Technical Analysis

Technical Analysis SentimentNegative
Last Price0.41

Price Trends

50DMA0.42Negative
100DMA0.49Negative
200DMA0.57Negative

Market Momentum

MACD0.02Negative
RSI50.45Neutral
STOCH68.81Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:BLO, the sentiment is Negative. The current price of 0.41 is above the 20-day moving average (MA) of 0.39, below the 50-day MA of 0.42, and below the 200-day MA of 0.57, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 50.45 is Neutral, neither overbought nor oversold. The STOCH value of 68.81 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:BLO.

Cannabix Technologies Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

TSE:BLO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
TSE:VPTTSE:VPT46NeutralCAD 15.43M-6.1356.40%―89.06%37.62%
TSE:BLOTSE:BLO43NeutralCAD 51.12M-13.23-232.36%――-84.43%
TSE:PINKTSE:PINK38UnderperformCAD 27.62M-1.41-303.05%―35.27%58.34%

* Healthcare Sector Average

Performance Comparison

0%50%100%150%TSE:BLOTSE:PINKTSE:VPTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26
TSE:BLO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
TSE:BLOCannabix0.41-0.12-21.70%
TSE:PINKPerimeter Medical Imaging Ai Inc0.18-0.05-23.40%
TSE:VPTVentriPoint Diagnostics0.08-0.02-20.00%

Cannabix Technologies Corporate Events

Business Operations and StrategyProduct-Related Announcements

Cannabix launches DOT-like breath-based multi-drug test panel for recent-use detection

Positive
Oct 20, 2026

Cannabix Technologies Inc., a Vancouver-based developer of breath-based marijuana and alcohol testing solutions, focuses on non-invasive tools that enhance public and workplace safety by identifying recent impairment rather than historical drug use....

Business Operations and StrategyProduct-Related Announcements

Cannabix Files Patent for Rapid Point-of-Care Marijuana Breath Test

Positive
Oct 14, 2026

Cannabix Technologies has filed a U.S. provisional patent application for a rapid, point-of-care marijuana breath test that combines its proprietary Breath Collection Unit and Breath Cartridge with lateral flow assay platforms. The proposed system is...

Business Operations and StrategyProduct-Related Announcements

Cannabix’s BreathLogix Enters U.S. Manufacturing Market with Alabama Deployment

Positive
Sep 29, 2026

Cannabix Technologies has deployed its BreathLogix alcohol screening solution at a manufacturing facility in Alabama, marking the product’s first delivery to a U.S.-based manufacturing company. The system, distributed through reseller AlcoPro,...

Business Operations and StrategyProduct-Related Announcements

Cannabix Expands BreathLogix Alcohol Monitoring Deployment in Montana

Positive
Aug 21, 2026

Cannabix Technologies has deployed its BreathLogix alcohol screening system at the Big Horn County Misdemeanor Probation and Pre-trial Services department in Montana, expanding its footprint under the state’s 24/7 Sobriety Program. The device,...

Business Operations and StrategyProduct-Related Announcements

Cannabix Targets Combat Sports for Marijuana Breath Test Rollout

Positive
Aug 5, 2026

Cannabix Technologies Inc., listed on the CSE, OTC and Frankfurt exchanges, develops marijuana and alcohol breath-testing technologies aimed at workplace and public safety markets. Its flagship Marijuana Breath Test targets recent THC use through rap...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 22, 2026